Abstract Context The European Association of Urology (EAU) Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …

Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …

Background Patients with clear cell renal cell carcinoma (ccRCC) with venous tumor
thrombus have a poor prognosis, high surgical risk, and lack of targeted therapeutic agents …

Abstract In KEYNOTE-564, adjuvant pembrolizumab, a PD-1 antibody, significantly
improved disease-free survival (DFS) in localised clear-cell renal cell carcinoma (ccRCC) …

Historically, kidney cancer was approached in a siloed single-speciality way, with urological
surgeons managing the localised stages of the disease and medical oncologists caring for …

Renal cell carcinoma (RCC) is a common urinary tract tumor that arises from the highly
heterogeneous epithelium of the renal tubules. The incidence of kidney cancer is second …

The clinical management of advanced malignancies of the upper and lower urinary tract has
been revolutionized with the advent of immune checkpoint blockers (ICBs). ICBs reinstate or …

Renal cell carcinoma (RCC) accounts for 2–3% of all malignant disease in adults, with 30%
of RCC diagnosed at locally advanced or metastatic stages of disease. A form of locally …

Objectives To synthesise available data regarding the disease‐free survival (DFS) benefit of
adjuvant immune checkpoint inhibitors (ICIs) for patients with renal cell carcinoma (RCC) …

The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel
has compiled these clinical guidelines to provide urologists with evidence-based information …